Thrombophilia related issues in women and children.
Women experience increased thrombotic risk at pregnancy and puerperium as well as during hormonal therapy with oral contraceptives or hormone replacement therapy. Physiological and anatomical changes in pregnancy contribute to the hypercoagulable situation. Women with thrombophilia have an increased risk for venous and arterial thromboembolism as well as for gestational vascular complications including fetal loss, pre-eclampsia, placental abruption, and fetal growth restriction. Children are at increased thrombotic risk, particularly at the neonatal period, and may express thrombosis often in association with thrombophilia. This article will focuses on the clinical association, pathogenesis, and treatment of thrombophilia-related issues in women and children.
Hoffman
Ron
R
Head of Inpatient Hematology Unit, Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, Bruce Rappaport Faculty of Medicine, Haifa, Israel.
Brenner
Benjamin
B
D000925:Anticoagulants / Q000627:therapeutic use; D002648:Child; D003276:Contraceptives, Oral; D005165:Factor V / Q000235:genetics; D005260:Female; D005317:Fetal Growth Retardation; D020249:Hormone Replacement Therapy; D006801:Humans; D020138:Hyperhomocysteinemia / Q000235:genetics; D007231:Infant, Newborn; D009154:Mutation; D011247:Pregnancy; D011516:Prothrombin / Q000235:genetics; D012306:Risk; D019851:Thrombophilia / Q000175:diagnosis* / Q000209:etiology / Q000235:genetics / Q000378:metabolism; D013927:Thrombosis; D020246:Venous Thrombosis / Q000209:etiology
D000925:Anticoagulants; D003276:Contraceptives, Oral; C095381:factor V Leiden; D005165:Factor V; D011516:Prothrombin